Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Bayer : New Environmental and Molecular Mutagenesis Study Findings Have Been Reported by Researchers at Bayer (Classification of in vitro genotoxicants using...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:27pm CET

New Environmental and Molecular Mutagenesis Study Findings Have Been Reported by Researchers at Bayer (Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test)

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators publish new report on Environmental and Molecular Mutagenesis. According to news originating from Berlin, Germany, by NewsRx correspondents, research stated, "Regulatory in vitro genotoxicity testing exhibits shortcomings in specificity and mode of action (MoA) information. Thus, the aim of this work was to evaluate the performance of the novel MultiFlow assay composed of mechanistic biomarkers quantified in TK6 cells after treatment (4 and 24 hr): gH2AX (DNA double strand breaks), phosphorylated H3 (mitotic cells), translocated p53 (genotoxicity), and cleaved PARP1 (apoptosis)."

Our news journalists obtained a quote from the research from Bayer, "A reference dataset of 31 compounds with well-established MoA was studied using the MicroFlow micronucleus assay. A positive call was raised following the earlier published criteria from Litron Laboratories. In the light of our data, these evaluation criteria should probably be adjusted since only 8/11 (73%) nongenotoxicants and 18/20 (90%) genotoxicants were correctly identified. Moreover, there is a need for new in vitro tools to delineate the predominant MoA as in the MicroFlow assay only 5/9 (56%) aneugens and 4/11 (36%) clastogens were correctly classified. In contrast, the MultiFlow assay provides more in-depth information about the MoA and therefore reliably discriminates clastogens, aneugens, and nongenotoxicants. By using a lab-specific, practical threshold for the aforementioned biomarkers, 10/11 (91%) nongenotoxicants and 19/20 genotoxicants (95%), 9/11 (82%) clastogens, and 8/9 (89%) aneugens were correctly categorized, suggesting a clear improvement over the MicroFlow. Furthermore, the MultiFlow markers were benchmarked against established methods to assess the validity of the data. Altogether, these findings demonstrated good agreement between the MultiFlow assay and the benchmarking methods."

According to the news editors, the research concluded: "Finally, p21 may improve class discrimination given the correct identification of 4/4 (100%) aneugens and 2/5 (40%) clastogens."

For more information on this research see: Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test. Environmental and Molecular Mutagenesis, 2017;():. (Wiley-Blackwell - www.wiley.com/; Environmental and Molecular Mutagenesis - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1098-2280)

The news correspondents report that additional information may be obtained from S. Wilde, Investigational Toxicology, Bayer AG, Berlin, Germany. Additional authors for this research include M. Dambowsky, C. Hempt, A. Sutter and N. Queisser (see also Environmental and Molecular Mutagenesis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/em.22130. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Berlin, Europe, Germany, Genetics, Environmental and Molecular Mutagenesis.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
03:47pMONSANTO : Bayer Gets Green Light to Buy Monsanto
03:25pEuropean Union approves Bayer's acquisition of Monsanto, with conditions
01:52pEU Approves Bayer's Acquisition of Monsanto, With Conditions -- Update
01:50pBayer wins EU approval for $62.5 billion Monsanto buy
12:25pBAYER : $71,303 Federal Contract Awarded to NovaMed
12:22pEU Approves Bayer's Acquisition of Monsanto, With Conditions
03/20Monsanto backs new company focussed on gene editing, not GMOs
03/20BAYER : and Ginkgo Bioworks Form Joint Venture Named Joyn Bio
03/20Canadian National Railway Company (CNR) Analysts See $1.09 EPS; Last Week Bay..
03/15BAYER : Researchers Submit Patent Application, "Antibody and Protein Formulation..
More news
News from SeekingAlpha
07:16aEU approves Bayer's takeover of Monsanto 
03/20Bayer and Ginkgo Bioworks unveil joint venture, Joyn Bio, establish operation.. 
03/15Monsanto -5% as Bayer tie-up reportedly faces more antitrust hurdles 
03/14REUTERS : Bayer sees progress in talks with Russia over Monsanto deal 
03/13ROAD TO FINANCIAL INDEPENDENCE : My February 88-Stock Portfolio Review With Big .. 
Financials (€)
Sales 2018 35 876 M
EBIT 2018 7 359 M
Net income 2018 4 846 M
Debt 2018 5 116 M
Yield 2018 2,99%
P/E ratio 2018 16,48
P/E ratio 2019 14,72
EV / Sales 2018 2,30x
EV / Sales 2019 2,22x
Capitalization 77 460 M
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 119 €
Spread / Average Target 27%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-9.39%95 032
JOHNSON & JOHNSON-6.79%349 387
PFIZER1.55%216 268
NOVARTIS-5.90%213 387
ROCHE HOLDING LTD.-10.99%199 363
MERCK AND COMPANY-2.90%147 293